Trump-Pfizer Deal Softens Tariff Blow, Sets Precedent for Drugmakers

President Donald Trump’s long-anticipated threat to impose pharmaceutical tariffs may be losing its bite following a landmark drug pricing agreement struck with Pfizer on September 30, 2025. The deal signals a potential shift in the administration’s strategy, offering a pathway for other major drugmakers to avoid impending levies.

Under the Tuesday agreement, Pfizer committed to voluntarily lowering U.S. drug prices for Medicaid and pledged an additional $70 billion in domestic manufacturing and research investments. In return, the pharmaceutical giant secured a three-year exemption from specific pharmaceutical tariffs, providing crucial relief and clarity for the company and the broader industry.

The White House has indicated that it will prioritize securing similar voluntary agreements with other companies before implementing tariffs. Commerce Secretary Howard Lutnick confirmed that negotiations would be allowed to conclude before any Section 232 pharmaceutical-specific levies are imposed. President Trump stated he is actively working with other drugmakers, with Eli Lilly expected to be the next to finalize a pact. Many major pharmaceutical firms, including Johnson & Johnson, AstraZeneca, AbbVie, Roche, Novo Nordisk, and Amgen, have already increased U.S. investments, anticipating such negotiations.

Market reaction was positive, with Pfizer shares climbing over 6% and Eli Lilly up 5% on Tuesday. Analysts believe the Pfizer deal provides a blueprint for other companies to navigate Trump’s policies, potentially steering away from more punitive measures like the ‘most-favored-nation’ policy in favor of negotiated concessions and domestic investment.

阅读中文版 (Read Chinese Version)

Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.